Related Experiment Video
Updated: Nov 15, 2025

07:20
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
1.5K
My Treatment Approach to Multiple System Atrophy.
Elizabeth A Coon1, J Eric Ahlskog1
1Department of Neurology, Mayo Clinic, Rochester, MN.
Mayo Clinic Proceedings
|March 6, 2021
Summary
Multiple system atrophy (MSA) is a rare neurodegenerative disease. This guideline simplifies management by integrating tertiary and local care providers for better patient outcomes.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Multiple system atrophy (MSA) presents diagnostic and management challenges.
- It is characterized by autonomic failure and either parkinsonism or cerebellar ataxia.
- Current management often requires collaboration between tertiary and local care providers.
Purpose of the Study:
- To bridge the gap between tertiary and local care providers for multidisciplinary MSA patient care.
- To provide a simplified, evidence-based guideline for managing MSA symptoms.
- To empower a collaborative partnership between patients, tertiary specialists, and primary care providers.
Main Methods:
- Review of clinical experience and treatment strategies from a dedicated MSA clinic.
- Integration of subspecialty expertise throughout the disease course.
- Development of a practical guideline for managing complex, chronic MSA problems.
Main Results:
- The manuscript offers a practical guideline for managing MSA based on clinical experience.
- It emphasizes a team approach involving primary care providers and subspecialists.
- The guideline aims to simplify treatment strategies for common MSA symptoms.
Conclusions:
- Multidisciplinary care and collaboration are essential for effective MSA management.
- A simplified, integrated approach can improve patient outcomes and care coordination.
- Empowering primary care providers is key to managing this complex neurodegenerative disorder.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Alzheimer's Disease: Treatment
565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
Parkinson's Disease: Treatment
740
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
740
Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Atherosclerosis III: Management
111
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
111
Treatment Strategies for Psychological Disorders
428
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
428

